CPIX - CIK 0001087294
CUMBERLAND PHARMACEUTICALS INC trades as CPIX. In its fiscal 2025 annual report the company posted revenue of $44.52M, up 17.6% from the prior year and net income of -$2.84M. This page tracks CUMBERLAND PHARMACEUTICALS INC through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years CUMBERLAND PHARMACEUTICALS INC's revenue grew from $33.03M to $44.52M, a compound annual growth rate of 3.4%. Net profit margin compressed from -2.9% to -6.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| DEFM14A | - | 2026-05-26 |
| PREM14A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-05 |
| Major company event | 8-K | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Major company event | 8-K | 2026-04-23 |
| Insider trade | 4 | 2026-03-20 |
The largest companies sharing CUMBERLAND PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).
CUMBERLAND PHARMACEUTICALS INC reported revenue of $44.52M for fiscal year 2025, an increase of 17.6% year over year.
In its latest fiscal year CUMBERLAND PHARMACEUTICALS INC reported a net loss of $2.84M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.